Clinical Cancer Research, Vol 3, Issue 10 1739-1745, Copyright © 1997 by American Association for Cancer Research

ARTICLES

5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells

KR Johnson, L Wang, MC Miller 3rd, MC Willingham and W Fan
Department of Pathology, Experimental Oncology, Medical University of South Carolina, Charleston, South Carolina 29425, USA.

Paclitaxel, a naturally occurring antimitotic agent, has shown efficacy in the treatment of certain solid tumors, particularly metastatic breast carcinoma and drug-refractory ovarian cancers. Recent studies have demonstrated that paclitaxel, in addition to its effects on microtubules and cell cycle arrest, possesses significant cell-killing activity in solid tumor cells by the induction of apoptosis. However, the mechanism by which paclitaxel leads to cell death and its relationship with paclitaxel-induced mitotic arrest is presently unclear. In this study, we attempted to determine whether pre-arresting tumor cells at other phases of the cell cycle could affect paclitaxel-induced apoptosis. We found that 5-fluorouracil (5-FU), another antineoplastic agent that usually arrests tumor cells at the G1-S phase of the cell cycle, could significantly repress the cell-killing activity of paclitaxel in solid tumor cells, even when it was added simultaneously with paclitaxel. Further studies indicated that 5-FU actually inhibits the cytotoxic effects of paclitaxel on both mitotic arrest and apoptotic cell death, suggesting that 5-FU might interfere with paclitaxel cytotoxicity at an early stage, probably by preventing tumor cells from entering G2-M phase. Because recent clinical trials have used a combination of paclitaxel and 5-FU in the treatment of metastatic breast cancers, our results also suggest that the combination of these two drugs might not be as valuable in clinical chemotherapy.

This article has been cited by other articles:

				A. Vogt, P. R. McDonald, A. Tamewitz, R. P. Sikorski, P. Wipf, J. J. Skoko III, and J. S. Lazo A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells Mol. Cancer Ther., February 1, 2008; 7(2): 330 - 340. [Abstract] [Full Text] [PDF]

				N. Kikuno, N. Moriyama-Gonda, T. Yoshino, T. Yoneda, S. Urakami, M. Terashima, M. Yoshida, H. Kishi, K. Shigeno, H. Shiina, et al. Blockade of Paclitaxel-Induced Thymidine Phosphorylase Expression Can Accelerate Apoptosis in Human Prostate Cancer Cells Cancer Res., October 15, 2004; 64(20): 7526 - 7532. [Abstract] [Full Text] [PDF]

				M. Sui, J. M. Dziadyk, X. Zhu, and W. Fan Cell Cycle-Dependent Antagonistic Interactions between Paclitaxel and {gamma}-Radiation in Combination Therapy Clin. Cancer Res., July 15, 2004; 10(14): 4848 - 4857. [Abstract] [Full Text] [PDF]

				Y. Huang, Y. Fang, J. Wu, J. M. Dziadyk, X. Zhu, M. Sui, and W. Fan Regulation of Vinca alkaloid-induced apoptosis by NF-{kappa}B/I{kappa}B pathway in human tumor cells Mol. Cancer Ther., March 1, 2004; 3(3): 271 - 277. [Abstract] [Full Text]

				P. Nadella, C. Shapiro, G. A. Otterson, M. Hauger, S. Erdal, E. Kraut, S. Clinton, M. Shah, M. Stanek, P. Monk, et al. Pharmacobiologically Based Scheduling of Capecitabine and Docetaxel Results in Antitumor Activity in Resistant Human Malignancies J. Clin. Oncol., June 1, 2002; 20(11): 2616 - 2623. [Abstract] [Full Text] [PDF]

				E. Auzenne, N. J. Donato, C. Li, E. Leroux, R. E. Price, D. Farquhar, and J. Klostergaard Superior Therapeutic Profile of Poly-L-Glutamic Acid-Paclitaxel Copolymer Compared with Taxol in Xenogeneic Compartmental Models of Human Ovarian Carcinoma Clin. Cancer Res., February 1, 2002; 8(2): 573 - 581. [Abstract] [Full Text] [PDF]

				K. Fujimoto-Ouchi, Y. Tanaka, and T. Tominaga Schedule Dependency of Antitumor Activity in Combination Therapy with Capecitabine/5'-Deoxy-5-fluorouridine and Docetaxel in Breast Cancer Models Clin. Cancer Res., April 1, 2001; 7(4): 1079 - 1086. [Abstract] [Full Text]

				S. Zeng, Y. Z. Chen, L. Fu, K. R. Johnson, and W. Fan In Vitro Evaluation of Schedule-dependent Interactions between Docetaxel and Doxorubicin against Human Breast and Ovarian Cancer Cells Clin. Cancer Res., September 1, 2000; 6(9): 3766 - 3773. [Abstract] [Full Text]

				Y. Huang, K. R. Johnson, J. S. Norris, and W. Fan Nuclear Factor-{{kappa}}B/I{{kappa}}B Signaling Pathway May Contribute to the Mediation of Paclitaxel-induced Apoptosis in Solid Tumor Cells Cancer Res., August 1, 2000; 60(16): 4426 - 4432. [Abstract] [Full Text]

				K. R. Johnson, K. K. Young, and W. Fan Antagonistic Interplay between Antimitotic and G1-S Arresting Agents Observed in Experimental Combination Therapy Clin. Cancer Res., September 1, 1999; 5(9): 2559 - 2565. [Abstract] [Full Text] [PDF]